Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

Why AbbVie Expects Rova-T to Earn so Big in Peak Sales
Marketwatch
Sun, 07/10/16 - 12:07 pm
Tags:
AbbVie, Rova-T, Stemcentrx, lung cancer
Biogen, AbbVie: How Significant is the New MS Drug Zinbryta
Bidness, ETC
Wed, 07/6/16 - 10:54 am
Tags:
Biogen, AbbVie, Zinbryta, MS, multiple sclerosis
Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma
Market Realist
Wed, 07/6/16 - 09:48 am
Tags:
AbbVie, Imbruvica, diffuse large B-cell lymphoma
Generics giant Teva join PhRMA? AbbVie, others aren't having it
Fierce Pharma
Tue, 07/5/16 - 10:00 pm
Tags:
generics, Teva Pharmaceutical, AbbVie, PhRMA
Biotech: What's Ahead For The Second Half Of 2016
Seeking Alpha
Tue, 07/5/16 - 09:57 am
Tags:
biotech, AbbVie, Amgen, Allergan, Anacor, Gilead Sciences, Medivation, Pfizer, Sanofi
An Overnight Double! Could These Drugmakers Be Next?
Motley Fool
Sat, 07/2/16 - 12:36 pm
Tags:
Tesaro, ovarian cancer, PARP inhibitors, niraparib, AstraZeneca, Lynparza, Medivation, AbbVie, Clovis Oncology
Understanding Trinity: Inside the Testing of AbbVie’s Rova-T
Marketwatch
Fri, 07/1/16 - 12:15 pm
Tags:
AbbVie, Rova-T, small cell lung cancer
AbbVie Inc Bags Fourth Breakthrough Therapy Status for Imbruvica
Bidness, ETC
Thu, 06/30/16 - 09:35 am
Tags:
AbbVie, breakthrough therapies, Imbruvica, cGVHD, graft vs host disease
6 Biopharma Movers Making a Run on Wednesday
24/7 Wall St
Wed, 06/15/16 - 05:50 pm
Tags:
Aegerion, Cellectar, Infinity Pharma, AbbVie, QLT
AbbVie's Rova-T Update at ASCO: Good or Bad?
Motley Fool
Sun, 06/12/16 - 09:54 pm
Tags:
AbbVie, Rova-T, ASCO 2016, small cell lung cancer
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Motley Fool
Fri, 06/10/16 - 04:16 pm
Tags:
biotech, ASCO 2016, Biogen, Immunomedics, AbbVie, Juno Therapeutics, Kite Pharma
What AbbVie Bought for $5.8 Billion
Motley Fool
Mon, 06/6/16 - 11:25 am
Tags:
AbbVie, Stemcentrx, M&A, Rova-T, lung cancer
AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Yahoo
Mon, 06/6/16 - 11:23 am
Tags:
AbbVie, Imbruvica, CLL, small lymphocytic lymphoma, ASCO 2016
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
Yahoo
Sun, 06/5/16 - 12:03 pm
Tags:
AbbVie, glioblastoma, brain cancer, ASCO 2016, ABT-414
AbbVie's New Lung Cancer Drug May Extend Patients' Lives, But Could Disappoint Investors
Forbes
Sun, 06/5/16 - 11:50 am
Tags:
AbbVie, Rova-T, non-small cell lung cancer, ASCO 2016
AbbVie: Not Its First Rodeo
Seeking Alpha
Fri, 06/3/16 - 09:52 am
Tags:
AbbVie, Humira, patents
3 Stories To Watch At The Year’s Biggest Cancer Conference
Investors.com
Mon, 05/30/16 - 06:34 pm
Tags:
ASCO 2016, Pfizer, Eli Lilly, breast cancer, Ibrance, abemaciclib, AbbVie, non-small cell lung cancer, Rova-T, Keytruda, Bristol-Myers Squibb, Merck, Opdivo
Bet You Can't Guess Which of These 10 Big Pharma Names Has the Largest Late-Stage Pipeline
Motley Fool
Mon, 05/30/16 - 10:13 am
Tags:
JNJ, Pfizer, Novartis, Merck, Bristol-Myers Squibb, GSK, Sanofi, AbbVie, Eli Lilly, AstraZeneca
How Do Allergan’s Valuations Compare to Its Peers’?
Yahoo/Market Realist
Sat, 05/28/16 - 10:49 am
Tags:
Allergan, AbbVie, Pfizer, Merck
Biogen, AbbVie once-monthly MS injection wins U.S. approval
Yahoo/Reuters
Fri, 05/27/16 - 11:03 pm
Tags:
Biogen, AbbVie, MS, multiple sclerosis, FDA, Zinbryta

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.